Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Austin, Texas, Dec. 14, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Immuno-oncology Clinical Trials Market size was valued at USD 8.30 billion in 2023 and is expected to reach USD 23.63 billion by 2032, growing at a CAGR of 12.37% from 2024-2032. The market is driven by the increasing global cancer burden, significant R&D investments, and the success of novel immunotherapies like checkpoint inhibitors and CAR-T cell therapies. The U.S. Immuno-oncology Clinical Trials Market size was USD 3.08 billion in 2023 and is expected to reach USD 8.61 billion by 2032, growing at a CAGR of 12.15% over 2024-2032. The growing incidence of cancer and growing funding for immunotherapy research are driving the market's notable expansion. The need for clinical studies in this area has increased due to the emergence of checkpoint inhibitors, CAR-T cell treatments, and cancer vaccines. Get a Sample Report of Immuno-oncology Clinical Trials Market: https://www.snsinsider.com/sample-request
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Bank of America Corporation from $105.00 to $120.00. They now have a "buy" rating on the stock.MarketBeat
- Biotech Bill Bundled in Pentagon Spending Plan May Worsen Pharma's Patent Cliff Dilemma [Yahoo! Finance]Yahoo! Finance
- Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.MarketBeat
- Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIRâ„¢ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)Business Wire
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website